{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:41:33Z","timestamp":1790757693896,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH U24AT009676"],"award-info":[{"award-number":["NIH U24AT009676"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH\/NCI UG1CA189961"],"award-info":[{"award-number":["NIH\/NCI UG1CA189961"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00520-019-05063-x","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T15:03:58Z","timestamp":1567868638000},"page":"2553-2562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7938-6775","authenticated-orcid":false,"given":"Jennifer S.","family":"Gewandter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-1139","authenticated-orcid":false,"given":"Amber S.","family":"Kleckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley H.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Dworkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9828-9986","authenticated-orcid":false,"given":"Ian R.","family":"Kleckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya G.","family":"Mohile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Mustian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"key":"5063_CR1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81:772\u2013781","journal-title":"Ann Neurol"},{"key":"5063_CR2","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461\u20132470","journal-title":"Pain"},{"key":"5063_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/2193-1801-3-366","volume":"3","author":"B Bhatnagar","year":"2014","unstructured":"Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T (2014) Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. SpringerPlus 3:366","journal-title":"SpringerPlus"},{"key":"5063_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Cancer Netw 7:99\u2013108","journal-title":"J Natl Compr Cancer Netw"},{"key":"5063_CR5","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EML Smith","year":"2013","unstructured":"Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359\u20131367","journal-title":"JAMA"},{"key":"5063_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/WNL.0000000000006083","volume":"91","author":"JS Gewandter","year":"2018","unstructured":"Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O\u2019Mara A, Smith AG, Dastros-Pitei D et al (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology 91:403\u2013413","journal-title":"Neurology"},{"key":"5063_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58:323\u2013337","journal-title":"J Clin Epidemiol"},{"key":"5063_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00004479-199801000-00004","volume":"21","author":"JB Fowles","year":"1998","unstructured":"Fowles JB, Fowler EJ, Craft C (1998) Validation of claims diagnoses and self-reported conditions compared with medical records for selected chronic diseases. J Ambul Care Manage 21:24\u201334","journal-title":"J Ambul Care Manage"},{"key":"5063_CR9","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941\u20131967","journal-title":"J Clin Oncol"},{"key":"5063_CR10","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMp1809643","volume":"379","author":"R Platt","year":"2018","unstructured":"Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, Sherman RE (2018) The FDA sentinel initiative\u2014an evolving national resource. N Engl J Med 379:2091\u20132093","journal-title":"N Engl J Med"},{"key":"5063_CR11","unstructured":"Sentinel Modular Programs (2018) Querying tools: overview of functionality and technical documentation. US Food and Drug Administration, White Oak, MD"},{"key":"5063_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","volume":"6","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657\u2013666","journal-title":"Nat Rev Neurol"},{"key":"5063_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/jnci\/djz011","volume":"111","author":"SG Dorsey","year":"2019","unstructured":"Dorsey SG, Kleckner IR, Barton D, Mustian K, O\u2019Mara A, St. Germain D, Cavaletti G, Danhauer SC, Hershman DL, Hohmann AG et al (2019) The National Cancer Institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst 111:531\u2013537","journal-title":"J Natl Cancer Inst"},{"key":"5063_CR14","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.18632\/oncotarget.23467","volume":"9","author":"RJ Wadia","year":"2018","unstructured":"Wadia RJ, Stolar M, Grens C, Ehrlich BE, Chao HH (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322\u20137331","journal-title":"Oncotarget"},{"key":"5063_CR15","first-page":"1","volume":"0","author":"A Shah","year":"2018","unstructured":"Shah A, Hoffman EM, Mauermann M, Loprinzi CL, Windebank AJ, Klein CJ, Staff NP (2018) Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry 0:1\u20136","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5063_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.clcc.2017.03.013","volume":"16","author":"MJ Raphael","year":"2017","unstructured":"Raphael MJ, Fischer HD, Fung K, Austin PC, Anderson GM, Booth CM, Singh S (2017) Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clin Colorectal Cancer 16:397\u2013404 e391","journal-title":"Clin Colorectal Cancer"},{"key":"5063_CR17","doi-asserted-by":"crossref","unstructured":"Greenwald MK, Ruterbusch JJ, Beebe-Dimmer JL, Simon MS, Albrecht TL, Schwartz AG (2019) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer 125(2):269\u2013277","DOI":"10.1002\/cncr.31798"},{"key":"5063_CR18","first-page":"13377","volume":"39","author":"S Tesfaye","year":"1996","unstructured":"Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD, Group TEIS (1996) Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 39:13377\u201311384","journal-title":"Diabetologia"},{"key":"5063_CR19","unstructured":"Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, Hurria A, Kimmick G, Le-Rademacher JG, Lichtman S, et al (2018) Age and the risk of paclitaxel-induced neuropathy in women with early-stage breast cancer (Alliance A151411): results from 1,881 patients from cancer and leukemia group B (CALGB) 40101. Oncologist 24(5):617\u2013623"},{"key":"5063_CR20","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/annonc\/mdx491","volume":"28","author":"SB Park","year":"2017","unstructured":"Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, Friedlander M (2017) Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol 28:2733\u20132740","journal-title":"Ann Oncol"},{"key":"5063_CR21","doi-asserted-by":"crossref","unstructured":"Bulls HW, Hoogland AI, Kennedy B, James BW, Arboleda BL, Apte S, Chon HS, Small BJ, Gonzalez BD, Jim HSL (in press) A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecol Oncol 152(2):310\u2013315","DOI":"10.1016\/j.ygyno.2018.12.002"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05063-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05063-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05063-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T19:10:28Z","timestamp":1599333028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05063-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,7]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["5063"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05063-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,7]]},"assertion":[{"value":"29 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jennifer S. Gewandter has received consulting income in the past 36\u00a0months from MundiPharma, Disarm Therapeutics, Asahi Kasei Pharma, and SK Life Science. Ian R. Kleckner has received funding from the National Institutes of Health (K07CA221931). Robert H. Dworkin has received in the past 36\u00a0months research grants and contracts from US Food and Drug Administration and US National Institutes of Health, and compensation for consulting on clinical trial methods from Abide, Adynxx, Analgesic Solutions, Aptinyx, Asahi Kasei, Astellas, AstraZeneca, Biogen, Biohaven, Boston Scientific, Braeburn, Celgene, Centrexion, Chromocell, Clexio, Concert, Decibel, Dong-A, Eli Lilly, Eupraxia, Glenmark, Grace, Hope, Immune, Lotus Clinical Research, Mainstay, Neumentum, NeuroBo, Novaremed, Novartis, Pfizer, Phosphagenics, Quark, Reckitt Benckiser, Regenacy (also equity), Relmada, Sandoz, Scilex, Semnur, Sollis, Teva, Theranexus, Trevena, and Vertex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Harvard Pilgrim Health Care Institutional Review Board (IRB) determined that the project does not meet the definition of human subject research under the purview of the IRB according to federal regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}